A226330 Share Price Performance
Recent A226330 News & Updates
No updates
SyntekaBio, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -886.85
- Gross Margin
- 99.54%
- Net Profit Margin
- -1,375.93%
- Debt/Equity Ratio
- 102.0%
SyntekaBio, Inc. Competitors
About A226330
- Founded
- 2009
- Employees
- 62
- CEO
- WebsiteView website
SyntekaBio, Inc. operates as an artificial intelligence new drug development company based on genomic big data primarily in South Korea. It derives new drug candidates using DeepMatcher, an AI drug development platform that combines new drug development technology and genomic big data technology. The company also researches and develops biomarker detection for individual cancer drug screening, disease susceptibility, immune typing, pharmacogenomic typing, and multi-omics information-based drug side effect prediction technology. The company was founded in 2009 and is headquartered in Daejeon, South Korea.
South Korean Market Performance
- 7 Days: -2.5%
- 3 Months: 19.7%
- 1 Year: 13.3%
- Year to Date: 27.4%
Over the last 7 days, the market has dropped 2.5%, driven by a decline of 8.3% in the Financials sector. In the last year, the market is actually up 13%. Earnings are forecast to grow by 22% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading